Company intelligence / Profile preview

Psychedelic Pharma Corp.

Miami, Florida, United States

Ownership: Private
Development stage: Other

Overview

Psychedelic Pharma Corp. is a biopharmaceutical company dedicated to developing next-generation psychedelic therapies for neuropsychiatric conditions. The company focuses on refining the pharmacological profiles of compounds like psilocybin and MDMA to enhance therapeutic efficacy while minimizing adverse effects. By leveraging a proprietary drug discovery platform, PPC aims to create a pipeline of novel chemical entities that promote neuroplasticity. Their business model encompasses both internal drug development and strategic partnerships for clinical-stage advancement.

Therapeutic areas: Psychiatry
Modalities: Small moleculeNeuroplastogen
Industry: Biotech

Beyond the preview

Go deeper on Psychedelic Pharma Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psychedelic Pharma Corp..

Explore the full profile